Baird ‘encouraged’ by Allogene CAR-T therapy update
Baird says Allogene Therapeutics’s (ALLO) cemacabtagene ansegedleucel data update is positive. The firm is “quite encouraged” by the update, ...
Truist Financial Sticks to Its Buy Rating for Allogene Therapeutics (ALLO)
In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Allogene Therapeutics (ALLO – Research ...
Healio23h
FDA accepts IND for allogenic CAR T-cell therapy that could bypass lymphodepletion
The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI ...
Optimism In War On Cancer On The Rise, As Biotech Companies Roll Out More Wins - Financial News Media
CONTINUED... Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the m ...
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
Watsco reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $2.16 per share. The company reported quarterly sales of $1.75 billion which beat the analyst ...